P/E ratio for Alkermes (ALKS)
P/E ratio as of May 2024 (TTM): 18.8
According to Alkermes's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 18.8385. At the end of 2022 the company had a P/E ratio of -27.2.
P/E ratio history for Alkermes from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -27.2 | -64.89% |
| 2021 | -77.5 | 172.37% |
| 2020 | -28.5 | 75.82% |
| 2019 | -16.2 | -51.17% |
| 2018 | -33.2 | -37.6% |
| 2017 | -53.1 | 30.98% |
| 2016 | -40.6 | -22.32% |
| 2015 | -52.2 | -82.16% |
| 2014 | -293 | -200.82% |
| 2013 | 290 | -680.23% |
| 2012 | -50.1 | 75.88% |
| 2011 | -28.5 | 13.56% |
| 2010 | -25.1 | 9.19% |
| 2009 | -23.0 | -390.93% |
| 2008 | 7.89 | -5.37% |
| 2007 | 8.34 | -93.14% |
| 2006 | 122 | -208.07% |
| 2005 | -112 | 650.34% |
| 2004 | -15.0 | 76.54% |
| 2003 | -8.49 | 97.71% |
| 2002 | -4.29 | -86.48% |
| 2001 | -31.8 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 10.7 | -42.95% | 🇺🇸 USA |
 Novartis NVS | 27.6 | 46.63% | 🇨🇭 Switzerland |
 Pfizer PFE | 15.3 | -19.01% | 🇺🇸 USA |
 Sanofi SNY | 15.6 | -17.38% | 🇫🇷 France |
 Bristol-Myers Squibb BMY | 11.3 | -40.22% | 🇺🇸 USA |
 AstraZeneca AZN | 38.8 | 106.02% | 🇬🇧 UK |
 Zogenix ZGNX | -6.56 | -134.80% | 🇺🇸 USA |
 Acorda Therapeutics
ACOR | -0.0676 | -100.36% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | -8.55 | -145.36% | 🇮🇱 Israel |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.